Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jan;38(1):61–65. doi: 10.1128/aac.38.1.61

Clinical trial of sparfloxacin for lepromatous leprosy.

G P Chan 1, B Y Garcia-Ignacio 1, V E Chavez 1, J B Livelo 1, C L Jimenez 1, M L Parrilla 1, S G Franzblau 1
PMCID: PMC284397  PMID: 8141581

Abstract

Nine previously untreated patients with lepromatous leprosy were treated with 200 mg of sparfloxacin daily for 12 weeks to determine whether this drug is bactericidal for Mycobacterium leprae in humans. The efficacy of therapy was monitored both clinically and by measuring changes in morphological index, mouse footpad infectivity, and the radiorespirometric activity of M. leprae organisms obtained from serial biopsy specimens and also by determining titers of phenolic glycolipid-I in serum. Most patients showed clinical improvement within 2 weeks of treatment; this was accompanied by significant reductions in the morphological index, mouse footpad infectivity, and bacillary radiorespirometric activity. After 4 weeks of treatment, all patients had a morphological index of zero and specimens from most patients were noninfectious for mice, while the median decrease in radiorespirometric activity was > 99%. Overall results by the rapid radiorespirometric assay paralleled those of the mouse footpad and morphological index assays. Sparfloxacin given at 200 mg once daily appears to be rapidly bactericidal in humans, with activity similar to that observed in a previous clinical trial with 400 mg of ofloxacin.

Full text

PDF
61

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chanteau S., Cartel J. L., Perani E., N'Deli L., Roux J., Grosset J. H. Relationships between PGL-1 antigen in serum, tissue and viability of Mycobacterium leprae as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Lepr Rev. 1990 Dec;61(4):330–340. doi: 10.5935/0305-7518.19900030. [DOI] [PubMed] [Google Scholar]
  2. Cho S. N., Cellona R. V., Fajardo T. T., Jr, Abalos R. M., dela Cruz E. C., Walsh G. P., Kim J. D., Brennan P. J. Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Int J Lepr Other Mycobact Dis. 1991 Mar;59(1):25–31. [PubMed] [Google Scholar]
  3. Cho S. N., Hunter S. W., Gelber R. H., Rea T. H., Brennan P. J. Quantitation of the phenolic glycolipid of Mycobacterium leprae and relevance to glycolipid antigenemia in leprosy. J Infect Dis. 1986 Mar;153(3):560–569. doi: 10.1093/infdis/153.3.560. [DOI] [PubMed] [Google Scholar]
  4. Franzblau S. G., Biswas A. N., Jenner P., Colston M. J. Double-blind evaluation of BACTEC and Buddemeyer-type radiorespirometric assays for in vitro screening of antileprosy agents. Lepr Rev. 1992 Jun;63(2):125–133. doi: 10.5935/0305-7518.19920016. [DOI] [PubMed] [Google Scholar]
  5. Franzblau S. G., Parrilla M. L., Chan G. P. Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis. 1993 Mar;61(1):66–69. [PubMed] [Google Scholar]
  6. Franzblau S. G., White K. E. Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae. Antimicrob Agents Chemother. 1990 Feb;34(2):229–231. doi: 10.1128/aac.34.2.229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gelber R. H., Fukuda K., Byrd S., Murray L. P., Siu P., Tsang M., Rea T. H. A clinical trial of minocycline in lepromatous leprosy. BMJ. 1992 Jan 11;304(6819):91–92. doi: 10.1136/bmj.304.6819.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gelber R. H., Iranmanesh A., Murray L., Siu P., Tsang M. Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice. Antimicrob Agents Chemother. 1992 Nov;36(11):2544–2547. doi: 10.1128/aac.36.11.2544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gidoh M., Tsutsumi S. Activity of sparfloxacin against Mycobacterium leprae inoculated into footpads of nude mice. Lepr Rev. 1992 Jun;63(2):108–116. [PubMed] [Google Scholar]
  10. Grosset J. H., Ji B. H., Guelpa-Lauras C. C., Perani E. G., N'Deli L. N. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990 Jun;58(2):281–295. [PubMed] [Google Scholar]
  11. Johnson J. H., Cooper M. A., Andrews J. M., Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother. 1992 Nov;36(11):2444–2446. doi: 10.1128/aac.36.11.2444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rastogi N., Goh K. S. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother. 1991 Sep;35(9):1933–1936. doi: 10.1128/aac.35.9.1933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Roche P. W., Britton W. J., Neupane K. D., Failbus S. S., Cho S. N., Theuvenet W. J. The response to chemotherapy of serum Mycobacterium leprae-specific antigen in multibacillary leprosy patients. Am J Trop Med Hyg. 1991 Jun;44(6):702–708. doi: 10.4269/ajtmh.1991.44.702. [DOI] [PubMed] [Google Scholar]
  15. Shepard C. C. A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad-inoculation. Lepr Rev. 1981 Dec;52(4):299–308. doi: 10.5935/0305-7518.19810040. [DOI] [PubMed] [Google Scholar]
  16. Shepard C. C. Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 1982 Mar;50(1):96–101. [PubMed] [Google Scholar]
  17. Tsutsumi S., Gidoh M. Studies on the development of novel anti-leprous chemotherapeutics using nude mice with special reference to a new quinolone carboxylic acid, AT-4140. Nihon Rai Gakkai Zasshi. 1989 Oct-Dec;58(4):250–258. doi: 10.5025/hansen1977.58.250. [DOI] [PubMed] [Google Scholar]
  18. Young D. B., Harnisch J. P., Knight J., Buchanan T. M. Detection of phenolic glycolipid I in sera from patients with lepromatous leprosy. J Infect Dis. 1985 Nov;152(5):1078–1081. doi: 10.1093/infdis/152.5.1078. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES